Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Michael Matthay MD

Michael A. Matthay MD

Professor, Medicine and Anesthesia; Associate Director, Critical Care Medicine; Senior Associate, Cardiovascular Research Institute, Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, California

Dr. Matthay's overall focus is on improving clinical care of patients with acute respiratory failure from the acute respiratory distress syndrome and from sepsis. His research work has focused on basic, clinical, and translational studies to determine the pathogenesis of acute lung injury, with a major focus on understanding the human biology and clinical determinants that account for the development and resolution of ARDS, pneumonia and sepsis.

Dr. Matthay’s laboratory developed the ex vivo perfused human lung preparation to facilitate mechanistic studies of the pathogenesis of acute lung injury and to test potential new therapies, including studies of human bone marrow derived mesenchymal stromal cells (MSCs). He has is the principal investigator on several trials testing novel therapies for ARDS including MSCs. Dr. Matthay spends a considerable time mentoring physicians and faculty in career development and academic medicine.


Dr. Matthay’s work is supported by funding from NIH grants (NHLBI and NIAID), the Department of Defense, California Institute for Regenerative Medicine, as well as industry supported grants from Genentech Roche and Quantum Health.

Dr. Matthay has consulting work with Novartis, Johnson and Johnson, Merck, Gilead, Citius Pharmaceuticals, and Pliant Therapeutics.